İsteğe bağlı ürün analizi
İzninizle, hangi araştırma yolculuklarının işe yaradığını anlamak için gizliliği gözeten sınırlı analizler kullanırız. Reklam izleyicileri veya oturum kaydı kullanmayız. Bu seçimi Tercihler bölümünden değiştirebilirsiniz. Okuyun Gizlilik Politikası.
The Procter & Gamble Company's published Reduce conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $340.1B | |
|---|---|---|
| Revenue (ttm) | 87.9B | |
| Net income (ttm) | 15.7B | |
| EPS (ttm) | $6.64 | |
| Shares out | 2.3B | |
| P/E (trailing) | 23.9x | |
| P/E (forward) | 21.1x | |
| Dividend | $4.35 (2.75%) | |
| Volume | 3,382,574 | |
| Beta | 0.38 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2022-06-30 | 2023-06-30 | 2024-06-30 | 2025-06-30 | 2026-06-30 | Trend |
| Revenue | $80.19B | $82.01B | $84.04B | $84.28B | $87.03B | +2.1% |
| Gross profit | $38.03B | $39.25B | $43.19B | $43.12B | $43.67B | +3.5% |
| Operating income | $17.81B | $18.13B | $18.55B | $20.45B | $19.75B | +2.6% |
| Net income | $14.74B | $14.65B | $14.88B | $15.97B | $16.05B | +2.1% |
| EPS (diluted) | $5.81 | $5.90 | $6.02 | $6.51 | $6.62 | +3.3% |
| EBITDA | $21.24B | $21.77B | $22.58B | $23.92B | $21.25B | +0.0% |
| R&D | $2.00B | $2.00B | $2.00B | $2.10B | $2.10B | +1.2% |
| SG&A | $20.22B | $21.11B | $23.31B | $22.67B | $23.92B | +4.3% |
Recent company headlines from major financial publishers.
The base case is modest compounding, not a sharp reacceleration. A miss against either annual revenue anchor would disconfirm it by FY2028.
Upside requires FY2028 earnings to meet the forecast, FY2026 cash generation to persist, and the FY2024-to-FY2026 decline in diluted shares to continue. A miss against the FY2028 forecast or weaker operating cash would disconfirm this path.
| Ke ↓ / g → | 1.5% | 2.0% | 2.5% | 3.0% | 3.5% |
|---|---|---|---|---|---|
| 5.0% | $151 | $163 | $180 | $204 | $244 |
| 6.0% | $131 | $138 | $146 | $158 | $173 |
| 7.0% | $117 | $121 | $126 | $133 | $141 |
| 8.0% | $107 | $110 | $113 | $117 | $122 |
| 9.0% | $99.4 | $102 | $104 | $107 | $110 |
Upcoming earnings date and setup when available.
Her ay yayımlanan araştırma sürümünün taşıdığı derecelendirme. Bir derecelendirme, analiz tarihindeki fiyatı gerçeğe uygun değerle karşılaştırır; tahminin doğru çıkıp çıkmadığının kaydı değildir.
| Yıl | Oca | Şub | Mar | Nis | May | Haz | Tem | Ağu | Eyl | Eki | Kas | Ara |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |